

Novel tests for active tuberculosis

Dr. Matthias Stehr, Lionex, Braunschweig, Germany

Abstract

Tuberculosis (TB) is still one of the top 10 causes of death worldwide in 2018. In 2018, there were an estimated 10 million new TB cases. Globally, the TB mortality rate fell by 42% between 2000 and 2018, partly due to improved methods for the diagnosis of TB. But still, approximately one-third of the global burden of tuberculosis (TB) remains undiagnosed each year and the vast majority of cases of multidrug-resistant TB remain undetected. During the past 10 years, there has been substantial progress within the TB diagnostics developmental pipeline.

LIONEX has developed and produced several novel and cost-effective diagnostics for tuberculosis, based on a series of proprietary platforms. One focus of research is the development of novel tests for endemic countries. Consideration is also given to the requirements of future diagnostic tests.